Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B
Journal of Biological Chemistry · 2026
DOI: 10.1016/j.jbc.2026.113178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Imanol Zubiete-Franco und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, New York, USA. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 1, Spasms, Infantile, Epileptic Syndromes, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Coins for Alzheimer's Research Trust, Dane G. Hansen Foundation.
Abstract (Originalsprache)
CDKL5-deficiency disorder or CDD, which results in intellectual disability, speech, and motor deficits, and seizures that can start as early as 6 weeks after birth, is caused by de novo mutations in the CDKL5 gene. In early 2022, the FDA approved ganaxolone (Commercial name: Ztalmy) for the treatment of seizures in CDD patients 2 years and older. Ganaxolone has been reported to act as a GABAA receptor agonist that helps reduce neuronal excitability; however, based on its chemical structure, we hypothesized that ganaxolone may also act as a PTP1B inhibitor. We observed that ganaxalone was able to inhibit PTP1B activity both in an in vitro assay of enzyme activity and in different cell models, with similar potency to known inhibitors of PTP1B, including MSI-1436, which has a similar chemical structure. Additionally, inhibition of PTP1B in differentiating SH-SY5Y cells increased TRKB/BDNF signaling. This effect was prominent in CDKL5-KO cells, which have increased PTP1B expression. In these cells, inhibition of PTP1B not only brought BDNF signaling to levels similar to those of WT cells but also restored cellular morphology. Our results suggest that, like in Rett syndrome, targeting PTP1B may be a beneficial therapeutic strategy for CDD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, New York, USA.
- Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, New York, USA; Graduate Program in Genetics, Stony Brook University, Stony Brook, New York, USA.
- Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, New York, USA. Electronic address: tonks@cshl.edu.
Förderung
- NCI NIH HHS
- Coins for Alzheimer's Research Trust
- Dane G. Hansen Foundation
- Cold Spring Harbor Laboratory
- National Institutes of Health
Zitieren
APA
Zubiete-Franco, I., Hu, Q., Alves, S. R., Utama, R., & Tonks, N. K. (2026). Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.113178
Vancouver
Zubiete-Franco I, Hu Q, Alves SR, Utama R, Tonks NK. Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.113178
BibTeX
@article{ZubieteFranco2026,
author = {Zubiete-Franco, Imanol and Hu, Qingting and Alves, Steven R and Utama, Raditya and Tonks, Nicholas K},
title = {Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B},
journal = {Journal of Biological Chemistry},
year = {2026},
doi = {10.1016/j.jbc.2026.113178}
}
EUVIMED